Taysha Gene Therapies, Inc. Shares Outstanding (Cover Page)
Taysha Gene Therapies, Inc. (TSHA) had Shares Outstanding (Cover Page) of 325.83 million shares as of 2026-08-11, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-11
- 2026-08-11: Entity Common Stock, Shares Outstanding 325.83M shares.
- 2026-05-06: Entity Common Stock, Shares Outstanding 287.36M shares.
- 2026-03-19: Entity Common Stock, Shares Outstanding 287.27M shares.
- 2025-11-04: Entity Common Stock, Shares Outstanding 273.92M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-11 | 325.83M shares 10-Q · filed 2026-08-11 |
| 2026-05-06 | 287.36M shares 10-Q · filed 2026-05-06 |
| 2026-03-19 | 287.27M shares 10-K · filed 2026-03-19 |
| 2025-11-04 | 273.92M shares 10-Q · filed 2025-11-04 |
| 2025-08-12 | 272.79M shares 10-Q · filed 2025-08-12 |
| 2025-05-15 | 214.66M shares 10-Q · filed 2025-05-15 |
| 2025-02-26 | 205.00M shares 10-K · filed 2025-02-26 |
| 2024-11-13 | 204.94M shares 10-Q · filed 2024-11-13 |
| 2024-08-12 | 204.94M shares 10-Q · filed 2024-08-12 |
| 2024-05-14 | 187.02M shares 10-Q · filed 2024-05-14 |
| 2024-03-19 | 187.02M shares 10-K · filed 2024-03-19 |
| 2023-11-14 | 186.96M shares 10-Q · filed 2023-11-14 |
| 2023-08-14 | 64.47M shares 10-Q · filed 2023-08-14 |
| 2023-05-11 | 64.18M shares 10-Q · filed 2023-05-11 |
| 2023-04-24 | 64.18M shares 10-K/A · filed 2023-04-27 |
| 2023-03-28 | 63.47M shares 10-K · filed 2023-03-28 |
| 2022-11-08 | 62.44M shares 10-Q · filed 2022-11-08 |
| 2022-08-11 | 41.09M shares 10-Q · filed 2022-08-11 |
| 2022-05-16 | 40.55M shares 10-Q · filed 2022-05-16 |
| 2022-03-31 | 38.47M shares 10-K · filed 2022-03-31 |
| 2021-11-10 | 38.47M shares 10-Q · filed 2021-11-10 |
| 2021-08-16 | 38.39M shares 10-Q · filed 2021-08-16 |
| 2021-05-11 | 37.92M shares 10-Q · filed 2021-05-11 |
| 2021-03-03 | 37.76M shares 10-K · filed 2021-03-03 |
| 2020-11-12 | 37.76M shares 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |